Maravai LifeSciences Quarterly Balance Sheets Chart
Quarterly
|
Annual
Maravai LifeSciences Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||
| current assets: | |||||||||||||||||||
| cash and cash equivalents | 269,907,000 | 285,053,000 | 322,399,000 | 578,157,000 | 573,171,000 | 561,691,000 | 574,962,000 | 579,605,000 | 580,176,000 | ||||||||||
| accounts receivable | 27,882,000 | 28,493,000 | 38,520,000 | 28,873,000 | 38,651,000 | 36,685,000 | 54,605,000 | 45,674,000 | 48,987,000 | 56,273,000 | 138,624,000 | 114,069,000 | 120,354,000 | 120,355,000 | 117,512,000 | 65,939,000 | 83,534,000 | 121,821,000 | 51,018,000 |
| inventory | 46,667,000 | 49,773,000 | 50,082,000 | 50,409,000 | 49,294,000 | 49,846,000 | 51,397,000 | 49,142,000 | 47,402,000 | 54,819,000 | 43,152,000 | 62,424,000 | 60,113,000 | 51,409,000 | 51,557,000 | 56,246,000 | 47,781,000 | 47,129,000 | 33,301,000 |
| prepaid expenses and other current assets | 15,305,000 | 12,963,000 | 18,145,000 | 21,659,000 | 17,063,000 | 16,818,000 | 17,830,000 | 22,916,000 | 22,515,000 | 25,532,000 | 25,798,000 | 23,432,000 | 19,664,000 | 15,902,000 | 19,698,000 | 17,395,000 | 13,432,000 | 8,918,000 | 11,095,000 |
| total current assets | 359,761,000 | 376,282,000 | 429,146,000 | 679,098,000 | 685,362,000 | 667,884,000 | 699,912,000 | 700,865,000 | 699,312,000 | 765,513,000 | 847,902,000 | 835,526,000 | 759,382,000 | 619,135,000 | 740,039,000 | 687,478,000 | 644,491,000 | 425,543,000 | 331,598,000 |
| property and equipment | 162,727,000 | 166,428,000 | 164,474,000 | 164,555,000 | 165,503,000 | 161,628,000 | 162,900,000 | 153,565,000 | 141,619,000 | 87,721,000 | 52,694,000 | 48,420,000 | 46,956,000 | 47,702,000 | 46,332,000 | 108,322,000 | 104,751,000 | 105,133,000 | 101,305,000 |
| goodwill | 129,429,000 | 159,878,000 | 159,878,000 | 171,790,000 | 326,029,000 | 326,029,000 | 326,029,000 | 326,029,000 | 326,459,000 | 326,569,000 | 283,668,000 | 283,535,000 | 283,535,000 | 283,535,000 | 152,766,000 | 152,766,000 | 152,766,000 | 224,275,000 | 224,275,000 |
| intangible assets | 193,066,000 | 199,581,000 | 194,957,000 | 201,858,000 | 207,249,000 | 214,118,000 | 220,987,000 | 227,856,000 | 234,726,000 | 241,578,000 | 216,663,000 | 222,899,000 | 229,153,000 | 235,405,000 | 117,571,000 | 121,225,000 | 125,116,000 | 172,616,000 | 177,656,000 |
| other assets | 51,983,000 | 57,582,000 | 59,789,000 | 60,914,000 | 63,465,000 | 74,982,000 | 77,622,000 | 85,579,000 | 92,735,000 | 127,035,000 | 115,589,000 | 87,399,000 | 72,419,000 | 64,243,000 | 53,451,000 | 4,106,000 | 4,026,000 | 4,300,000 | 4,158,000 |
| total assets | 896,966,000 | 959,751,000 | 1,008,244,000 | 1,278,215,000 | 1,447,608,000 | 1,444,641,000 | 1,487,450,000 | 2,267,553,000 | 2,264,437,000 | 2,315,388,000 | 2,282,315,000 | 2,248,899,000 | 2,171,799,000 | 2,043,230,000 | 1,918,276,000 | 1,894,683,000 | 1,601,247,000 | 1,351,768,000 | 1,270,691,000 |
| liabilities and stockholders’ equity | |||||||||||||||||||
| current liabilities: | |||||||||||||||||||
| accounts payable | 11,525,000 | 9,525,000 | 11,957,000 | 9,494,000 | 12,536,000 | 8,226,000 | 10,729,000 | 9,424,000 | 6,658,000 | 4,784,000 | 5,991,000 | 9,459,000 | 23,267,000 | 10,384,000 | 8,154,000 | 8,917,000 | 11,704,000 | 9,806,000 | 8,171,000 |
| accrued expenses and other current liabilities | 50,202,000 | 44,603,000 | 36,407,000 | 38,498,000 | 40,719,000 | 35,405,000 | 60,237,000 | 56,042,000 | 50,344,000 | 70,065,000 | 53,371,000 | 60,187,000 | 43,641,000 | 32,411,000 | 34,574,000 | 31,422,000 | 24,794,000 | 28,973,000 | 38,546,000 |
| deferred revenue | 1,639,000 | 2,756,000 | 2,375,000 | 1,834,000 | 2,078,000 | 2,210,000 | 3,360,000 | 2,553,000 | 2,459,000 | 2,053,000 | 3,088,000 | 5,822,000 | 5,435,000 | 3,693,000 | 10,211,000 | 66,715,000 | 109,490,000 | 119,175,000 | 78,061,000 |
| current portion of long-term debt | 5,440,000 | 5,440,000 | 5,440,000 | 5,440,000 | 5,440,000 | 5,440,000 | 5,440,000 | 5,440,000 | 5,440,000 | 5,440,000 | 5,440,000 | 5,440,000 | 5,440,000 | 5,440,000 | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 |
| current portion of finance lease liabilities | 876,000 | 834,000 | 792,000 | 750,000 | 710,000 | 672,000 | 633,000 | 596,000 | 560,000 | ||||||||||
| total current liabilities | 69,682,000 | 63,158,000 | 56,971,000 | 63,241,000 | 68,552,000 | 59,022,000 | 87,468,000 | 78,253,000 | 74,919,000 | 124,896,000 | 110,144,000 | 115,655,000 | 112,530,000 | 86,675,000 | 93,777,000 | 114,352,000 | 164,773,000 | 165,252,000 | 130,778,000 |
| long-term debt, less current portion | 288,436,000 | 289,499,000 | 290,492,000 | 516,283,000 | 517,083,000 | 517,893,000 | 518,707,000 | 519,520,000 | 520,336,000 | 521,161,000 | 521,997,000 | 522,824,000 | 523,655,000 | 524,499,000 | 524,591,000 | 525,584,000 | 526,583,000 | 527,593,000 | 528,614,000 |
| finance lease liabilities, less current portion | 30,651,000 | 30,881,000 | 31,106,000 | 31,327,000 | 31,527,000 | 31,714,000 | 31,897,000 | 32,077,000 | 32,236,000 | ||||||||||
| deferred tax liabilities | 2,028,000 | 1,974,000 | 6,690,000 | 8,512,000 | 8,680,000 | 8,571,000 | 8,609,000 | ||||||||||||
| other long-term liabilities | 38,186,000 | 43,966,000 | 52,466,000 | 54,237,000 | 54,032,000 | 58,623,000 | 59,494,000 | 64,531,000 | 62,862,000 | 66,052,000 | 68,975,000 | 57,519,000 | 50,590,000 | 66,522,000 | 41,066,000 | 1,553,000 | 1,057,000 | 2,310,000 | 2,231,000 |
| total liabilities | 428,983,000 | 429,478,000 | 431,035,000 | 665,088,000 | 671,194,000 | 667,252,000 | 697,566,000 | 1,375,272,000 | 1,366,799,000 | 1,414,750,000 | 1,377,072,000 | 1,407,230,000 | 1,398,007,000 | 1,388,928,000 | 1,372,915,000 | 1,441,067,000 | 1,268,106,000 | 1,142,012,000 | 1,115,945,000 |
| commitments and contingencies | |||||||||||||||||||
| stockholders’ equity: | |||||||||||||||||||
| class a common stock | 1,446,000 | 1,440,000 | 1,420,000 | 1,416,000 | 1,415,000 | 1,327,000 | 1,322,000 | 1,319,000 | 1,319,000 | 1,318,000 | 1,317,000 | 1,315,000 | 1,315,000 | 1,315,000 | 1,315,000 | 1,314,000 | 1,143,000 | 966,000 | 966,000 |
| class b common stock | 1,107,000 | 1,107,000 | 1,107,000 | 1,107,000 | 1,107,000 | 1,191,000 | 1,191,000 | 1,191,000 | 1,191,000 | 1,191,000 | 1,237,000 | 1,237,000 | 1,237,000 | 1,237,000 | 1,237,000 | 1,262,000 | 1,433,000 | 1,610,000 | 1,610,000 |
| additional paid-in capital | 191,377,000 | 186,797,000 | 181,874,000 | 175,581,000 | 168,337,000 | 134,482,000 | 128,503,000 | 125,088,000 | 119,903,000 | 114,309,000 | 137,898,000 | 134,077,000 | 131,373,000 | 128,584,000 | 128,386,000 | 172,611,000 | 118,208,000 | 85,976,000 | 85,125,000 |
| retained earnings | 71,355,000 | 110,946,000 | 140,891,000 | 167,036,000 | 266,074,000 | 273,659,000 | 285,737,000 | 391,696,000 | 398,158,000 | 404,699,000 | 404,766,000 | 367,132,000 | 322,663,000 | 251,423,000 | 184,561,000 | 127,450,000 | 73,176,000 | 24,101,000 | 854,000 |
| accumulated other comprehensive income | 574,000 | 324,000 | |||||||||||||||||
| total stockholders’ equity attributable to maravai lifesciences holdings, inc. | 265,859,000 | 300,614,000 | 325,292,000 | 345,140,000 | 436,933,000 | 410,659,000 | 416,753,000 | 519,294,000 | 520,571,000 | 521,517,000 | 545,218,000 | 503,761,000 | |||||||
| non-controlling interest | 202,124,000 | 229,659,000 | 251,917,000 | 267,987,000 | 339,481,000 | 366,730,000 | 373,131,000 | 372,987,000 | 377,067,000 | 379,121,000 | 360,025,000 | 337,908,000 | 317,204,000 | 271,743,000 | 229,862,000 | 150,979,000 | |||
| total stockholders’ equity | 467,983,000 | 530,273,000 | 577,209,000 | 613,127,000 | 776,414,000 | 777,389,000 | 789,884,000 | 892,281,000 | 897,638,000 | 900,638,000 | 905,243,000 | 841,669,000 | |||||||
| total liabilities and stockholders’ equity | 896,966,000 | 959,751,000 | 1,008,244,000 | 1,278,215,000 | 1,447,608,000 | 1,444,641,000 | 1,487,450,000 | 2,267,553,000 | 2,264,437,000 | 2,315,388,000 | 2,282,315,000 | 2,248,899,000 | |||||||
| interest rate cap | 6,575,000 | ||||||||||||||||||
| current portion of payable to related parties pursuant to the tax receivable agreement | 7,225,000 | 7,069,000 | 7,069,000 | 7,069,000 | 4,198,000 | 9,458,000 | 42,254,000 | 42,254,000 | 34,747,000 | ||||||||||
| government funding receivable | 608,000 | 2,844,000 | 1,118,000 | 3,528,000 | 232,000 | 616,000 | 8,190,000 | 18,155,000 | 8,575,000 | ||||||||||
| deferred tax assets | 773,659,000 | 769,586,000 | 766,972,000 | 765,799,000 | 771,120,000 | 780,354,000 | 793,210,000 | 808,117,000 | 820,786,000 | 570,097,000 | 419,901,000 | 431,699,000 | |||||||
| payable to related parties pursuant to the tax receivable agreement, less current portion | 674,201,000 | 667,934,000 | 677,392,000 | 675,956,000 | 711,232,000 | ||||||||||||||
| cash | 628,273,000 | 632,138,000 | 617,446,000 | 550,676,000 | 431,469,000 | 551,272,000 | 547,898,000 | 374,710,000 | 247,675,000 | 236,184,000 | |||||||||
| current portion of finance lease obligations | 300,000 | ||||||||||||||||||
| finance lease obligations, less current portion | 16,569,000 | ||||||||||||||||||
| liabilities and stockholders' equity | |||||||||||||||||||
| current portion of payable to related parties pursuant to a tax receivable agreement | 34,747,000 | 34,747,000 | 34,838,000 | 1,298,000 | 1,298,000 | ||||||||||||||
| payable to related parties pursuant to a tax receivable agreement, less current portion | 711,232,000 | 711,232,000 | 713,481,000 | ||||||||||||||||
| stockholders' equity: | |||||||||||||||||||
| total stockholders' equity attributable to maravai lifesciences holdings, inc. | 456,588,000 | 382,559,000 | 315,499,000 | 302,637,000 | 193,921,000 | 112,611,000 | |||||||||||||
| total stockholders' equity | 773,792,000 | 654,302,000 | 545,361,000 | 453,616,000 | 333,141,000 | 209,756,000 | |||||||||||||
| total liabilities and stockholders' equity | 2,171,799,000 | 2,043,230,000 | 1,918,276,000 | 1,894,683,000 | 1,601,247,000 | 1,351,768,000 | |||||||||||||
| lease facility financing obligation, less current portion | 55,324,000 | 55,626,000 | 55,924,000 | 56,167,000 | |||||||||||||||
| accumulated other comprehensive loss | -39,000 | -42,000 | -44,000 | ||||||||||||||||
| payable to related parties pursuant to a tax receivable agreement | 744,254,000 | 520,067,000 | 382,362,000 | 389,546,000 | |||||||||||||||
| lease commitments | |||||||||||||||||||
| assets held for sale | 125,034,000 | ||||||||||||||||||
| liabilities related to assets held for sale | 11,487,000 | ||||||||||||||||||
| non-controlling interests | 139,220,000 | 97,145,000 | 66,235,000 | ||||||||||||||||
| current portion of payable to related parties pursuant to tax receivable agreement | 1,298,000 | ||||||||||||||||||
| stockholders' equity | |||||||||||||||||||
| liabilities and stockholders'/member’s equity | |||||||||||||||||||
| stockholders' / member's equity | |||||||||||||||||||
| member’s equity | |||||||||||||||||||
| total stockholders' / member's equity attributable to maravai lifesciences holdings, inc. | 88,511,000 | ||||||||||||||||||
| total stockholders' / member’s equity | 154,746,000 | ||||||||||||||||||
| total liabilities and stockholders' / member’s equity | 1,270,691,000 |
We provide you with 20 years of balance sheets for Maravai LifeSciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Maravai LifeSciences. Explore the full financial landscape of Maravai LifeSciences stock with our expertly curated balance sheets.
The information provided in this report about Maravai LifeSciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.